Beyond Pluripotency Harnessing Organ Specific Stem Cells for Therapeutic Innovation – A Review

Pradeep Mahajan; Pallavi Lale; Siddhant Mahajan; Sanskruti Mahajan; Jyoti Gupta; Marilyn Dsouza

doi:10.36948/ijfmr.2025.v07i06.60284

Beyond Pluripotency Harnessing Organ Specific Stem Cells for Therapeutic Innovation – A Review

Author(s)	Dr. Pradeep Mahajan, Dr. Pallavi Lale, Mr. Siddhant Mahajan, Dr. Sanskruti Mahajan, Ms. Jyoti Gupta, Ms. Marilyn Dsouza
Country	India
Abstract	Mesenchymal stem cells (MSCs) have transformed the landscape of regenerative medicine since their discovery in the 1970s, evolving from bone marrow–derived progenitors once regarded as universal repair cells to a diverse family of organ-specific variants adapted to distinct tissue microenvironments. This review traces the historical progression of MSC research—from early focus on trilineage differentiation and generalized therapeutic potential in the 1990s–2000s, through the recognition of source-dependent heterogeneity in the 2010s, to the present paradigm emphasizing organ-resident MSCs. Conventional MSC therapies are limited by poor homing efficiency (<1% engraftment), donor variability, and mismatched microenvironmental cues. In contrast, organ-specific MSCs exhibit enhanced paracrine activity, epigenetic priming, and tissue-aligned functionality that improve therapeutic outcomes. Drawing on transcriptomic, proteomic, and preclinical evidence, this review highlights the advantages of cardiac, hepatic, and endometrial MSCs in targeted applications such as myocardial repair, fibrosis attenuation, and reproductive tissue regeneration. Additionally, perinatal-derived MSCs (e.g., umbilical cord and placenta) demonstrate superior proliferative capacity and immunomodulatory potential compared to adult sources, making them promising candidates for allogeneic therapies. Despite these advances, challenges in standardization, potency assessment, and clinical translation persist. This synthesis underscores the growing need for precise source–disease matching to optimize MSC efficacy and safety, marking a shift toward personalized regenerative medicine. Organ-specific MSCs thus represent a major step forward in achieving more targeted, efficient, and clinically translatable cell-based therapies for inflammatory, degenerative, and organ-specific disorders.
Keywords	Mesenchymal Stem Cells, Organ-Specific MSCs, Regenerative Medicine, Therapeutic Heterogeneity, Perinatal MSCs, Precision Therapy
Field	Medical / Pharmacy
Published In	Volume 7, Issue 6, November-December 2025
Published On	2025-11-13
DOI	https://doi.org/10.36948/ijfmr.2025.v07i06.60284

View / Download PDF File

E-ISSN 2582-2160

doi

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads

Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 8 Isu 2 Cover Page Vol 8 Isu 1 Cover Page Vol 7 Isu 6

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9687-828-838	editor@ijfmr.com

International Journal For Multidisciplinary Research

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Beyond Pluripotency Harnessing Organ Specific Stem Cells for Therapeutic Innovation – A Review

Share this